Many individuals in economically disadvantaged countries succumb to treatable diseases because they lack the financial means to afford the necessary medication. In my view, pharmaceutical companies should indeed make their products available at reduced prices in these regions, and I will elaborate on why I hold this belief.
Primarily, pharmaceutical companies are morally obligated to reduce prices in low-income regions as it reflects the principles of a compassionate society. For instance, documentaries and news broadcasts often depict the tragic plight of people in Africa and Asia who perish simply because they cannot afford essential treatment. It is disheartening to witness the parallels between these individuals and those in more affluent nations. It is undeniably unethical to inflate prices for vital resources in these areas.
Furthermore, if drug companies decrease their prices in impoverished regions, the populace would have access to essential medication, ultimately leading to an enhancement in the overall welfare of these countries. For example, with a greater number of individuals receiving treatment, these countries could benefit from an expanded workforce, subsequently contributing to improvements in infrastructure and industrial growth. Consequently, this would lead to economic advancement within these nations.
In conclusion, it is my firm belief that the pharmaceutical industry should lower prices in economically disadvantaged areas in order to exhibit compassion and uplift the well-being of these regions.
